Generic placeholder image

Current Drug Targets - CNS & Neurological Disorders


ISSN (Print): 1568-007X
ISSN (Online): 1568-007X

The Plasma Membrane: A Target and Hurdle for the Development of Anti- A? Drugs?

Author(s): Patrice Talaga and Luc Quere

Volume 1 , Issue 6 , 2002

Page: [567 - 574] Pages: 8

DOI: 10.2174/1568007023338897

Price: $65


The plasma membrane has been the subject of intense investigation in the search for antiamyloidogenic drugs for the treatment of Alzheimers disease. Studies have highlighted numerous toxic properties of the well-known amyloid Aβ peptide on neuronal membranes. In this respect recent experimental data suggest that an early step in amyloid toxicity might be intracellularly mediated. This suggests that effective anti-amyloidogenic agents must be able to readily cross the plasma membrane while at the same time, counteracting the deleterious effects of the Aβ peptide on the phospholipid bilayer. This review summarizes recent findings regarding amyloid-plasma membrane interactions and discusses their relevance for the design of novel, potential anti-Aβ drugs.

Keywords: , plasma membrane, aggregation, intracellular toxicity, cholesterol, neuroprotection, alzheimer's disease, lipid bilayer

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy